Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A phase 2 study, investigating prevention and treatment algorism of the skin toxicity related with Panitumumab treatment in patients with unresectable and/or metastatic CRC with KRAS wild type refractory to 5-FU containing chemotherapy

ABSTRACT: Interventions: pre-emptive administration of minocycline hydrochloride 100mg twice per day and consistent heparinoid containing skin moisturizer, which are started at panitumumab contained chemotherapy started. And reactive treatment of topical steroid; Hydrocortisone butyrate cream 0.1% apply to face, diflupredonate ointment 0.05% apply to the other part. Primary outcome(s): incidence rates and timing of grade two or more skin toxicity during 6 weeks from Panitumumab contained chemotherapy started. Study Design: Single arm Non-randomized

DISEASE(S): Unresectable And/or Metastatic Colorectal Cancer

PROVIDER: 2621298 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

JAPANESE - Skin Toxicity Evaluation Protocol With Panitumumab as 3rd line treatment for Colorectal Cancer(J-STEPP),(HGCSG1001)

Project description:Interventions: panitumumab+skin moisturizers(8weeks) panitumumab+skinmoisturizers+sunscreen+minocycline+topical steroid(8weeks) Primary outcome(s): Adverce event of skin toxicity (>= grade2) during the 6 weeks from treatment started Study Design: Parallel Randomized

| 2620326 | ecrin-mdr-crc

A double-blind, controlled trial to evaluate the efficacy and safety of vitamin K1 ointment for cetuximab and Panitumumab-induced acneiform eruption

Project description:Interventions: 0.1% vitamin K1 ointment twice daily Placebo ointment twice daily Primary outcome(s): The number of acneiform eruptions of right and left lesions(face, neck, or chest) of the same patient before and after treatment Study Design: Parallel Randomized

| 2623509 | ecrin-mdr-crc

Investigation of the molecular effects of a dexpanthenol-containing ointment and liquid in the aftercare treatment of acute radiodermatitis and mucositis using newly developed 3D models for both skin conditions

Project description:This study aimed to investigate the molecular effects of radiation and subsequent aftercare treatment with dexpanthenol-containing ointment and liquid on newly established full-thickness 3D skin models depicting acute radiodermatitis and mucositis. We established in vitro models of the non-keratinized mucous membrane as well as normal human skin models. To mimic radiomucositis and radiodermatitis, models were irradiated with 5 Gray. Afterwards, models were treated topically every second day with dexpanthenol-containing ointment or liquid in comparison to placebo and untreated controls.

2020-05-19 | GSE150738 | GEO

Investigating basic information of skin toxicity associated with molecularly-targeted drugs cetuximab and panitumumab, and an evaluation of the usefulness of a topical moisturizer in patients treated for colorectal carcinoma and head and neck cancer.

Project description:Interventions: topical administration of heparinoid twice a day in six weeks none Primary outcome(s): sebum capacity, water content of the stratum corneum, duaring 6 weeks from cetuximab or Panitumumab contained chemotherapy started Study Design: Parallel Randomized

| 2635178 | ecrin-mdr-crc

Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment

Project description:Up to 60% of patients with metastatic colorectal cancer can be treated with one of monoclonal antibodies targeted against epidermal growth factor receptor (EGFR). This treatment is associated with a specific spectrum of toxicity: acne-like rash from limited up to erythema, often with severe pruritus, sometimes combined with other types of skin toxicities (hair and nail changes). Previously in STEPP study investigators shown that pre-emptive treatment with oral doxycycline (200 mg daily), topical steroids and sun blockers reduces the number of more severe skin side effects of panitumumab. The study is designed to described the profile of skin toxicity of EGFR blocking drugs combined with low-dose doxycycline (100 mg daily) used in the pre-emptive manner.

| 2108692 | ecrin-mdr-crc

Skin Toxicity Prevention Protocol with Panitumumab treatment for Metastatic Colorectal Cancer

Project description:Interventions: A group Panitumumab is administered intravenously in 6mg/kg by biweekly skin care+antibiotics Clarithromycin is administered orally twice a day B group Panitumumab is administered intravenously in 6mg/kg by biweekly skin care only Primary outcome(s): incidence rates of skin toxicity (>=Grade2) with or without antibiotics during the 6 weeks from the treatment started Study Design: Parallel Randomized

| 2626856 | ecrin-mdr-crc

Multicenter phase II trial of panitumumab plus irinotecan and S-1 (PIRIS regimen) in patients treated by oxaliplatin-based chemotherapy with K-RAS wild-type advanced colorectal cancer.

Project description:Interventions: Take care of skin before the PIRIS regimen (moistureizer,sunscreen,steroid, antibiotic). Day1/Day15 panitumumab 6mg/kg irinotecan 125mg/m2 Day1~14 S-1 80-120mg/m2 q4w(until progressive disease) Primary outcome(s): Response ratte : RR Study Design: Single arm Non-randomized

| 2620021 | ecrin-mdr-crc

RNA-Seq to probe transcription of patient-derived organotypic colorectal cancer.

Project description:Patient-derived cancer organoids (PCOs) provide a platform to model resistant to targeted therapies. Following culture maturation, PCOs were treated with stepwise dose escalation of EGFR inhibitors. Cultures were started at 20% physiologic Cmax panitumumab (46ug/ml) and assessed for growth (normalized change in diameter at 96 hours). If cultures surpassed ≥20% growth, stepwise dose escalation was repeated with interval increase of 20% Cmax. Time to resistant (TTR) was defined by duration of time from the initiation of dose escalation to persistent growth at 100% Cmax panitumumab. All samples were collected in triplicate biological replicates at baseline and after achieving resistance to EGFRi with persistent growth at 100% physiologic Cmax. RNA library was constructed using TruSeq Stranded total RNA with rRNA reduction (Illumina). Quality control was performed by Eukaryote Total RNA electrophoresis using NanoDropOne. The library included 2x150bp paired end reads with sequencing performed by NovaSeq 6000 using MiSeq NanoCell at University of Wisconsin Biotechnology Center.

2023-07-01 | GSE180480 | GEO

Profiling gene expression in M. tuberculosis under different in vitro conditions.

Project description:This RNA-Seq study of gene expression in M. tuberculosis was done as part of the FLUTE project (NIH grant U19-AI107774, Eric Rubin, program director). There are 3 replicates each for Mtb H37Rv grown under the following conditions: 0.1% butyrate, 0.4% glucose, butyrate+glucose, low iron, acidic conditions, and several RIF-resistant mutants of Beijing strain HN878 with different mutations in RpoB.

2016-03-30 | E-GEOD-67035 | biostudies-arrayexpress

The Effect of Anaesthetic Drugs on Recovery in Patients Undergoing Cancer surgery

Project description:Intervention1: KETAMINE: Patients will be randomised to receive low dose ketamine infusions @ 0.1 mg/kg/hr + GA + Epidural; ketamine infusion will be started around the time of skin incision Intervention2: DEXMEDETOMIDINE: : Dexmedetomidine IV infusions @ 0.25 mcg/kg/hr + GA + Epidural; dexmedetomidine infusion will be started around the time of skin incision around the time of incision Control Intervention1: NORMAL SALINE: 0.9 % Saline IV infusions @ 5 ml/hr Primary outcome(s): 1.To assess the effect of infusion of a low dose of ketamine and dexmedetomidine infusions vs placebo on the time to passage of flatus in patients undergoing GI malignancy surgeries.Timepoint: Post - Operatively 24 hrs to 72 hrs Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant, Investigator and Outcome Assessor Blinded

| 2582579 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data